Oncternal Therapeutics (NASDAQ:ONCT) Given Hold Rating at Brookline Capital Management

Brookline Capital Management reiterated their hold rating on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note published on Thursday morning, MarketBeat.com reports.

Other research analysts also recently issued research reports about the company. StockNews.com assumed coverage on Oncternal Therapeutics in a research note on Sunday, September 8th. They issued a hold rating for the company. HC Wainwright decreased their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating for the company in a report on Monday, August 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of Hold and an average target price of $20.00.

Oncternal Therapeutics Price Performance

Shares of ONCT stock opened at $1.46 on Thursday. The firm has a 50-day moving average of $5.37 and a 200-day moving average of $7.46. Oncternal Therapeutics has a one year low of $1.32 and a one year high of $13.14. The company has a market cap of $4.32 million, a P/E ratio of -0.12 and a beta of 1.39.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. The firm had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. During the same quarter last year, the firm earned ($3.00) EPS. As a group, research analysts expect that Oncternal Therapeutics will post -11.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission. 16.05% of the stock is currently owned by institutional investors and hedge funds.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.